Table 1 Characteristics of breast cancer patients in Eastern Morocco
Characteristics | Â |
|---|---|
Age at diagnosis (n = 2220) | |
 Mean (years ± SD) | 48.7 ± 11.4 |
 Median (years) | 48 |
Histological type (n = 2260) | |
 Invasive ductal carcinoma | 77.1% |
 Invasive lobular carcinoma | 15.3% |
 Medullary carcinoma | 1.9% |
 Mucinous carcinoma | 1.3% |
 Papillary carcinoma | 0.5% |
 Other types | 3.9% |
Tumor size (n = 1435) | |
 Mean (cm ± SD) | 3.5 ± 1.96 |
 Median (cm) | 3 |
  ≤ 2 cm | 16% |
  > 2 cm | 84% |
Histological grade SBR (n = 1538) | |
 I | 11.6% |
 II | 70.4% |
 III | 18% |
Lymph node status (n = 1426) | |
 N0 | 35.2% |
 N+ | 64.8% |
Metastasis status (n = 1311) | |
 M0 | 70.7% |
 M+ | 29.3% |
IHC markers status (n = 2260) | |
 ER+ and/or PR+ | 73% |
 ER+ | 64.2% |
 PR+ | 66.5% |
 HER2+ | 28.6% |
Use of targeted therapy among HRE2+ tumors | |
 Non | 31.1% |
 Herceptin (Trastuzumab) | 68.9% |
Use of hormone therapy among HR+ tumors | |
 No | 13.9% |
 Yes | 86.1% |
Therapy used among postmenopausal patients with HR+ tumor and treated with hormone therapy | |
 Tamoxifen | 79.3% |
 Aromatase inhibitors | 15.2% |
 Tamoxifen then Aromatase inhibitors | 5.5% |
Therapy used among premenopausal patients with HR+ tumor and treated with hormone therapy | |
 Tamoxifen | 100% |